JP2018522049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522049A5 JP2018522049A5 JP2018505714A JP2018505714A JP2018522049A5 JP 2018522049 A5 JP2018522049 A5 JP 2018522049A5 JP 2018505714 A JP2018505714 A JP 2018505714A JP 2018505714 A JP2018505714 A JP 2018505714A JP 2018522049 A5 JP2018522049 A5 JP 2018522049A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrate
- pharmaceutically acceptable
- acceptable salt
- formula
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200545P | 2015-08-03 | 2015-08-03 | |
| US201562200549P | 2015-08-03 | 2015-08-03 | |
| US201562200556P | 2015-08-03 | 2015-08-03 | |
| US62/200,549 | 2015-08-03 | ||
| US62/200,545 | 2015-08-03 | ||
| US62/200,556 | 2015-08-03 | ||
| US201562201009P | 2015-08-04 | 2015-08-04 | |
| US62/201,009 | 2015-08-04 | ||
| US201562235102P | 2015-09-30 | 2015-09-30 | |
| US62/235,102 | 2015-09-30 | ||
| PCT/US2016/043676 WO2017023584A1 (en) | 2015-08-03 | 2016-07-22 | Combination therapies for treating cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020171578A Division JP2021001237A (ja) | 2015-08-03 | 2020-10-09 | がん処置のための組み合わせ療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522049A JP2018522049A (ja) | 2018-08-09 |
| JP2018522049A5 true JP2018522049A5 (OSRAM) | 2019-09-05 |
| JP6815383B2 JP6815383B2 (ja) | 2021-01-20 |
Family
ID=56555867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505714A Expired - Fee Related JP6815383B2 (ja) | 2015-08-03 | 2016-07-22 | がん処置のための組み合わせ療法 |
| JP2020171578A Pending JP2021001237A (ja) | 2015-08-03 | 2020-10-09 | がん処置のための組み合わせ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020171578A Pending JP2021001237A (ja) | 2015-08-03 | 2020-10-09 | がん処置のための組み合わせ療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180207164A1 (OSRAM) |
| EP (1) | EP3331531A1 (OSRAM) |
| JP (2) | JP6815383B2 (OSRAM) |
| AU (1) | AU2016304172A1 (OSRAM) |
| CA (1) | CA2994265A1 (OSRAM) |
| HK (1) | HK1255939A1 (OSRAM) |
| TW (1) | TW201717953A (OSRAM) |
| WO (1) | WO2017023584A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114522167A (zh) * | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| EP3886840A4 (en) * | 2018-11-30 | 2022-08-24 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| WO2021157650A1 (ja) * | 2020-02-05 | 2021-08-12 | カルナバイオサイエンス株式会社 | 抗がん剤組成物 |
| WO2024037910A1 (en) * | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Syk inhibitors for use in the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015002947A (es) * | 2012-09-07 | 2015-09-23 | Genentech Inc | Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo. |
| AU2014251028A1 (en) * | 2013-04-08 | 2015-11-05 | Janssen Pharmaceutica Nv | Ibrutinib combination therapy |
| SG10201709926VA (en) * | 2013-05-30 | 2017-12-28 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| HK1222803A1 (zh) * | 2013-11-07 | 2017-07-14 | 豪夫迈．罗氏有限公司 | 抗cd20抗体与btk抑制剂的组合疗法 |
| TWI735853B (zh) * | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| SI3179992T1 (sl) * | 2014-08-11 | 2022-09-30 | Acerta Pharma B.V. | Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1 |
| TW201618772A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物 |
| EP3313405A1 (en) * | 2015-06-23 | 2018-05-02 | Gilead Sciences, Inc. | Combination therapies for treating b-cell malignancies |
-
2016
- 2016-07-22 JP JP2018505714A patent/JP6815383B2/ja not_active Expired - Fee Related
- 2016-07-22 HK HK18115008.8A patent/HK1255939A1/zh unknown
- 2016-07-22 EP EP16745381.0A patent/EP3331531A1/en not_active Withdrawn
- 2016-07-22 WO PCT/US2016/043676 patent/WO2017023584A1/en not_active Ceased
- 2016-07-22 CA CA2994265A patent/CA2994265A1/en not_active Abandoned
- 2016-07-22 US US15/749,222 patent/US20180207164A1/en not_active Abandoned
- 2016-07-22 AU AU2016304172A patent/AU2016304172A1/en not_active Abandoned
- 2016-07-22 TW TW105123357A patent/TW201717953A/zh unknown
-
2020
- 2020-10-09 JP JP2020171578A patent/JP2021001237A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024133474A5 (OSRAM) | ||
| JP2019501133A5 (OSRAM) | ||
| JP2014517050A5 (OSRAM) | ||
| JP2015535247A5 (OSRAM) | ||
| JP2014513136A5 (OSRAM) | ||
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| JP2015528471A5 (OSRAM) | ||
| JPWO2022014639A5 (OSRAM) | ||
| KR102634247B1 (ko) | 다발성 골수종을 치료하기 위한 약물 병용물 | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2014505735A5 (OSRAM) | ||
| CN105120868A (zh) | 组合治疗 | |
| JP2016536286A5 (OSRAM) | ||
| JP2008521928A5 (OSRAM) | ||
| JP2012530779A5 (OSRAM) | ||
| JP2013507415A5 (OSRAM) | ||
| JP2014500295A5 (OSRAM) | ||
| JP2015524472A5 (OSRAM) | ||
| JP2017529382A5 (OSRAM) | ||
| JP2017526677A5 (OSRAM) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2014525454A5 (OSRAM) | ||
| JP2014505107A5 (OSRAM) | ||
| JP2018522049A5 (OSRAM) | ||
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма |